TP53 P151H

CI-VAR-00003283Explore in graph →NP_000537.3:p.Pro151HisNM_000546.5:c.452C>AClinVar 376639 CIViC 1093 rs1057520000

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Unmapped disease2unmapped disease
TP53 P151H	(functional)	Functional	D	Supports Unaltered Function	2	submitted	EID9493 Fifty missense mutations identified in sporadic breast cancer were assessed for qualitative and quantitative changes in their ability to transactivate from 11 human promoter response elements in a yea… (full text at CIViC) PMID 20407015 · Jordan et al., 2010 · Open in CIViC	civic
TP53 P151H	(functional)	Functional	D	Does Not Support Dominant Negative	3	accepted	EID10222 A set of previously characterized p53 mutants was tested in the yeast assay to understand their transdominant potential (dominant negative). Each mutant was expressed equally with the wild-type p53. T… (full text at CIViC) PMID 11896595 · Monti et al., 2002 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
376639	Uncertain significance	criteria provided, single submitter	1	Ovarian neoplasm; Li-Fraumeni syndrome; Neoplasm; Embryonal rhabdomyosarcoma	germline/somatic	4	May 07, 2022	clinvar